Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears BD's Trichomoniasis Assay for Viper System

NEW YORK (GenomeWeb News) – BD Diagnostics said today that the US Food and Drug Administration has cleared the BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay to run on BD's Viper System with XTR Technology.

The assay is for the qualitative detection of T. vaginalis DNA in endocervical and vaginal samples, as well as neat urine samples, to aid in the diagnosis of trichomoniasis. The assay is also CE-IVD marked.

BD Diagnostics, a segment of Becton Dickinson, today also launched the product.

Running on the BD Viper System, the assay "reduces human intervention and associated variables and improves speed to results," the company said.

"The global prevalence of trichomoniasis is on the rise and there are more asymptomatic cases than previously thought," Chris Demiris, worldwide group marketing manager, BD Diagnostics – Diagnostic Systems, Women's Health and Cancer, said in a statement. "The availability of an automated platform is especially important as clinical and public health communities embrace the need for a test that provides timely and accurate diagnosis of trichomoniasis when screening high-risk populations."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.